Skip to main content
Top
Published in: Lung 5/2017

01-10-2017

Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study

Authors: Abhishek Gadre, Christian Ghattas, Xiaozhen Han, Xiaofeng Wang, Omar Minai, Kristin B. Highland

Published in: Lung | Issue 5/2017

Login to get access

Abstract

Background

Pulmonary hypertension (PH) is a common complication of scleroderma (SSc) and is a leading cause of morbidity and mortality.

Objectives

To explore the utility of the 6MWT in the prediction of SSc-PH and to assess its prognostic implications.

Methods

A retrospective review of SSc patients from 2003 to 2013, with 6MWT and echocardiogram (n = 286), was conducted. Presence of PH was defined by right heart catheterization. Patients were randomized into development and validation cohorts. Using regression techniques, we developed a scoring system to predict the presence of SSc-PH and tested it in our validation cohort. Trends of mortality and disease severity were studied for incremental scores.

Results

The DIBOSA scoring system includes DIstance walked in 6 min, BOrg dyspnea index, and SAturation of oxygen at 6 min. The DIBOSA score in the development cohort ranged from 0 to 3, resulting in an area of 0.858 (P < 0.0001) under the ROC curve. A score of 0 had a NPV of 100% and a score of 3 had a PPV of 86.58%. The validation cohort had an area under the ROC curve of 0.842. The DIBOSA score correlated with both pulmonary artery pressures and mortality. The 3-year survival rates for DIBOSA scores of 0, 1, 2, and 3 were 100, 100, 87.67, and 66.67%, respectively (HR = 3.92, P < 0.0001).

Conclusions

DIBOSA score is a sensitive tool for the prediction of SSc-PH. The DIBOSA score is a direct predictor of mortality in SSc-PH and strongly correlates with pulmonary pressures. 6MWT can be used to predict clinical outcomes in SSc-PH.
Literature
1.
go back to reference Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093CrossRefPubMedPubMedCentral Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093CrossRefPubMedPubMedCentral
2.
go back to reference Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52(12):3792–3800CrossRefPubMed Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52(12):3792–3800CrossRefPubMed
3.
go back to reference Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB et al (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138(6):1383–1394CrossRefPubMedPubMedCentral Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB et al (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138(6):1383–1394CrossRefPubMedPubMedCentral
4.
go back to reference Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093–2100CrossRefPubMed Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093–2100CrossRefPubMed
5.
go back to reference Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63(11):3522–3530CrossRefPubMed Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63(11):3522–3530CrossRefPubMed
6.
go back to reference Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE et al (2013) Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 65(12):3194–3201CrossRefPubMed Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE et al (2013) Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 65(12):3194–3201CrossRefPubMed
7.
go back to reference Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349CrossRefPubMed Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349CrossRefPubMed
8.
go back to reference Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C et al (2015) A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 17:7CrossRefPubMedPubMedCentral Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C et al (2015) A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 17:7CrossRefPubMedPubMedCentral
9.
go back to reference Meune C, Avouac J, Airò P, Beretta L, Dieudé P, Wahbi K et al (2011) Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 63(9):2790–2796CrossRefPubMed Meune C, Avouac J, Airò P, Beretta L, Dieudé P, Wahbi K et al (2011) Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 63(9):2790–2796CrossRefPubMed
10.
go back to reference Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 P 1):487–492CrossRefPubMed Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 P 1):487–492CrossRefPubMed
11.
go back to reference Garin MC, Highland KB, Silver RM, Strange C (2009) Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 36(2):330–336CrossRefPubMed Garin MC, Highland KB, Silver RM, Strange C (2009) Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 36(2):330–336CrossRefPubMed
12.
go back to reference Impens A, Wangkaew S, Seibold J (2008) The 6-minute walk test in scleroderma—how measuring everything measures nothing. Rheumatology 47(suppl 5):v68–v69CrossRefPubMed Impens A, Wangkaew S, Seibold J (2008) The 6-minute walk test in scleroderma—how measuring everything measures nothing. Rheumatology 47(suppl 5):v68–v69CrossRefPubMed
13.
go back to reference Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M (2001) Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 17(4):647–652CrossRefPubMed Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M (2001) Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 17(4):647–652CrossRefPubMed
14.
go back to reference Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA (2015) Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension. Pulm Circ 5(3):565–576CrossRefPubMedPubMedCentral Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA (2015) Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension. Pulm Circ 5(3):565–576CrossRefPubMedPubMedCentral
15.
go back to reference Laboratories ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117CrossRef Laboratories ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117CrossRef
16.
go back to reference Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975CrossRefPubMed Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975CrossRefPubMed
17.
go back to reference Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J et al (2009) Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 39(10):682–691CrossRefPubMed Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J et al (2009) Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 39(10):682–691CrossRefPubMed
18.
go back to reference Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36(2):239–243CrossRefPubMed Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36(2):239–243CrossRefPubMed
19.
go back to reference Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254CrossRefPubMed Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254CrossRefPubMed
22.
go back to reference Bursac Z, Gauss CH, Williams DK, Hosmer DW (2008) Purposeful selection of variables in logistic regression. Sour Code Biol Med 3:17CrossRef Bursac Z, Gauss CH, Williams DK, Hosmer DW (2008) Purposeful selection of variables in logistic regression. Sour Code Biol Med 3:17CrossRef
23.
go back to reference Hajian-Tilaki K (2013) Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med 4(2):627–635 Hajian-Tilaki K (2013) Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med 4(2):627–635
25.
go back to reference Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW (2010) A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 143(3):331–336CrossRefPubMedPubMedCentral Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW (2010) A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 143(3):331–336CrossRefPubMedPubMedCentral
26.
go back to reference Batal O, Khatib OF, Dweik RA, Hammel JP, McCarthy K, Minai OA (2012) Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving </=2 years and those surviving >/=5 years after baseline right-sided cardiac catheterization. Am J Cardiol 109(10):1514–1520CrossRefPubMed Batal O, Khatib OF, Dweik RA, Hammel JP, McCarthy K, Minai OA (2012) Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving </=2 years and those surviving >/=5 years after baseline right-sided cardiac catheterization. Am J Cardiol 109(10):1514–1520CrossRefPubMed
27.
go back to reference Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K, Dweik RA (2012) Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 185(4):400–408CrossRefPubMed Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K, Dweik RA (2012) Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 185(4):400–408CrossRefPubMed
28.
go back to reference Caminati A, Harari S (2010) IPF: new insight in diagnosis and prognosis. Respir Med 104(Suppl 1):S2–S10CrossRefPubMed Caminati A, Harari S (2010) IPF: new insight in diagnosis and prognosis. Respir Med 104(Suppl 1):S2–S10CrossRefPubMed
29.
go back to reference Tugwell P, Boers M, D’Agostino MA, Beaton D, Boonen A, Bingham CO 3rd et al (2014) Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of “truth”: content, face, and construct validity. J Rheumatol 41(5):1000–1004CrossRefPubMedPubMedCentral Tugwell P, Boers M, D’Agostino MA, Beaton D, Boonen A, Bingham CO 3rd et al (2014) Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of “truth”: content, face, and construct validity. J Rheumatol 41(5):1000–1004CrossRefPubMedPubMedCentral
30.
go back to reference Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA et al (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134(3):601–605CrossRefPubMed Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA et al (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134(3):601–605CrossRefPubMed
31.
go back to reference Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE (1996) Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 90(4):223–230CrossRefPubMed Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE (1996) Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 90(4):223–230CrossRefPubMed
32.
go back to reference Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66(6):754–763CrossRefPubMedPubMedCentral Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66(6):754–763CrossRefPubMedPubMedCentral
33.
go back to reference Follansbee WP, Zerbe TR, Medsger TA Jr (1993) Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 125(1):194–203CrossRefPubMed Follansbee WP, Zerbe TR, Medsger TA Jr (1993) Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 125(1):194–203CrossRefPubMed
Metadata
Title
Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study
Authors
Abhishek Gadre
Christian Ghattas
Xiaozhen Han
Xiaofeng Wang
Omar Minai
Kristin B. Highland
Publication date
01-10-2017
Publisher
Springer US
Published in
Lung / Issue 5/2017
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-017-0034-1

Other articles of this Issue 5/2017

Lung 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.